Tenax Therapeutics (TENX) 10-K2020 FY Annual report

Filed: 31 Mar 21, 4:31pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: abdominal, adjunct, affirmative, Aid, alter, amino, animal, annum, appetite, appoint, appointed, Armistice, ATP, attorney, bankruptcy, belief, bicycle, binding, bioavailability, biological, Breakthrough, cancer, capacity, capsule, cascade, central, certify, challenging, Chamber, Chancery, characterize, clarity, CML, collateral, Commerce, confounded, controversy, convene, cure, cytochrome, Davidson, Declan, default, denied, Department, Deregulation, diarrhea, differentiation, disbursed, distance, distention, doctrine, Doogan, Dr, dramatic, edema, electrocardiographic, entrench, enzyme, exert, faith, FC, fiduciary, fluid, forgiven, forum, fullest, gastric, Gleevec, headache, hearing, home, Horizon, imatinib, inaccurate, inapplicable, indispensable, inhaled, inhibitor, intestine, intolerance, journal, jurisdiction, kinase, led, leg, Lender, leukemia, liver, loan, manuscript, matter, media, merge, merged, metabolism, metabolized, methodology, mitigate, monthly, mortgage, myeloid, myelosuppression, nausea, noncancer, noncompliance, orphan, outpatient, overexpressed, owed, page, PAH, pathway, Paycheck, PDGF, PDGFRA, PHPM, PHPrecisionMed, platelet, PPP, preemption, prepay, progression, promptly, proper, protein, pyrimidine, qualification, RAP, rash, regression, regularly, Relief, repay, rest, revolutionized, Rich, SBA, securityholder, signaling, sixteen, size, solid, stabilizing, stimuli, Stockholm, stomach, Stuart, subcutaneously, subpart, succeeded, supine, surrogate, symptomatic, tired, tolerability, tolerated, tolled, tribunal, tyrosine, upcoming, verified, Virtual, vomiting, waiver, walk, week, worsening

Removed: accompanied, achieved, aortic, assistance, balloon, blind, CABG, component, consumption, coronary, COSO, decision, delisted, device, diminished, double, dropping, dual, essentially, execution, Fast, gradient, guided, headcount, heavily, hoc, improved, inclusion, increasing, index, infarction, initially, input, intracellular, isolated, Ladenburg, left, light, low, lt, LVEF, missing, mitral, myocardial, numerical, organ, outweigh, phosphodiesterase, poor, post, postoperative, powering, preoperative, presidential, prophylactically, prospectively, provisional, quad, randomize, relaxation, retroactively, revealed, rhythm, RV, sequelae, showed, slightly, SPA, split, sublicenseable, submitting, suggest, syndrome, Thalmann, Track, undergoing, valve

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

TENX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Tenax Therapeutics, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Anthony DiTonno, Chief Executive Officer (Principal Executive Officer) of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 31, 2021		/s/ Anthony DiTonno
		Anthony DiTonno
		Chief Executive Officer (Principal Executive Officer)

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350 and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.